U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H14FN6O6P.2Na
Molecular Weight 494.2814
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOREZOLID PHOSPHATE DISODIUM

SMILES

[Na+].[Na+].CN1N=NC(=N1)C2=NC=C(C=C2)C3=CC=C(C=C3F)N4C[C@H](COP([O-])([O-])=O)OC4=O

InChI

InChIKey=UAIJRGWLKLRQAH-CURYUGHLSA-L
InChI=1S/C17H16FN6O6P.2Na/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(30-17(24)25)9-29-31(26,27)28;;/h2-7,12H,8-9H2,1H3,(H2,26,27,28);;/q;2*+1/p-2/t12-;;/m1../s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=25136252

Tedizolid (also known as TR-700, DA-7157) as is an active compound, which is produced by plasma or intestinal phosphatases, after administration of the drug, tedizolid phosphate either orally or intravenously. The mechanism of action of tedizolid occurs through inhibition of bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the 70S initiation complex and inhibiting protein synthesis.

Originator

Dong-A Pharmaceutical
6
Curator's Comment: It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals)

Approval Year

2014
494
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
SIVEXTRO

Approved Use

Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria in adults. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Launch Date

2014
Curative
Approved
8429
SIVEXTRO

Approved Use

Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria in adults. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Launch Date

2014
Curative
Approved
8429
SIVEXTRO

Approved Use

Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria in adults. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.2 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.3 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg 1 times / day steady-state, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
23.8 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
25.6 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
26.6 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
29.2 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg 1 times / day steady-state, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg 1 times / day steady-state, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
200 mg 1 times / day steady-state, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
[NO STEREO] TEDIZOLID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, oral
Studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
healthy, 18-45 years
n = 6
Health Status: healthy
Age Group: 18-45 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
Disc. AE: Vomiting...
Other AEs: Diarrhea, Headache...
AEs leading to
discontinuation/dose reduction:
Vomiting (3 patients)
Other AEs:
Diarrhea (13%)
Headache (10.9%)
Nausea (6.5%)
Abdominal pain (4.3%)
Vomiting (4.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
400 mg single, intravenous
Highest studied dose
Dose: 400 mg
Route: intravenous
Route: single
Dose: 400 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/24989138
healthy, 29 years
n = 9
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/24989138
Sources:
https://pubmed.ncbi.nlm.nih.gov/24989138
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27317442
healthy, 31.0 years (range: 18–41)
n = 8
Health Status: healthy
Age Group: 31.0 years (range: 18–41)
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/27317442
Disc. AE: Reticulocyte count, White blood cell decreased...
AEs leading to
discontinuation/dose reduction:
Reticulocyte count (1 patient)
White blood cell decreased (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/27317442
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
unhealthy, 42 years (range: 17 - 86 years)
n = 662
Health Status: unhealthy
Age Group: 42 years (range: 17 - 86 years)
Population Size: 662
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
Disc. AE: Abdominal discomfort, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Abdominal discomfort (0.2%)
Diarrhea (0.2%)
Vomiting (0.2%)
Osteomyelitis (0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
AEs

AEs

AESignificanceDosePopulation
Headache 10.9%
1200 mg single, oral
Studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
healthy, 18-45 years
n = 6
Health Status: healthy
Age Group: 18-45 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
Diarrhea 13%
1200 mg single, oral
Studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
healthy, 18-45 years
n = 6
Health Status: healthy
Age Group: 18-45 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
Vomiting 3 patients
Disc. AE
1200 mg single, oral
Studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
healthy, 18-45 years
n = 6
Health Status: healthy
Age Group: 18-45 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
Abdominal pain 4.3%
1200 mg single, oral
Studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
healthy, 18-45 years
n = 6
Health Status: healthy
Age Group: 18-45 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
Vomiting 4.3%
1200 mg single, oral
Studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
healthy, 18-45 years
n = 6
Health Status: healthy
Age Group: 18-45 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
Nausea 6.5%
1200 mg single, oral
Studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
healthy, 18-45 years
n = 6
Health Status: healthy
Age Group: 18-45 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/27342387
Reticulocyte count 1 patient
Disc. AE
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27317442
healthy, 31.0 years (range: 18–41)
n = 8
Health Status: healthy
Age Group: 31.0 years (range: 18–41)
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/27317442
White blood cell decreased 1 patient
Disc. AE
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27317442
healthy, 31.0 years (range: 18–41)
n = 8
Health Status: healthy
Age Group: 31.0 years (range: 18–41)
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/27317442
Abdominal discomfort 0.2%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
unhealthy, 42 years (range: 17 - 86 years)
n = 662
Health Status: unhealthy
Age Group: 42 years (range: 17 - 86 years)
Population Size: 662
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
Diarrhea 0.2%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
unhealthy, 42 years (range: 17 - 86 years)
n = 662
Health Status: unhealthy
Age Group: 42 years (range: 17 - 86 years)
Population Size: 662
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
Osteomyelitis 0.2%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
unhealthy, 42 years (range: 17 - 86 years)
n = 662
Health Status: unhealthy
Age Group: 42 years (range: 17 - 86 years)
Population Size: 662
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
Vomiting 0.2%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
unhealthy, 42 years (range: 17 - 86 years)
n = 662
Health Status: unhealthy
Age Group: 42 years (range: 17 - 86 years)
Population Size: 662
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf
Page: p. 117
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587

inducer
781
substrate
1037

inhibitor
1767

inducer
389
substrate
1217

inhibitor
1852

inducer
97
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2B6
810

CYP2C8
911

CYP2C19
1478

OAT1
599

OAT3
642

OATP1B1
788

OATP1B3
706

OCT1
512

OCT2
647

P-gp
1461

BCRP
699
CYP1A2
1054

CYP2B6
664

CYP2C8
693

CYP2C19
991

OAT1
326

OAT3
339

OATP1B1
406

OATP1B3
350

OCT1
327

OCT2
355

P-gp
1537

SULT1A1
29

SULT2A1
24
CYP1A2
701

CYP2B6
547

CYP2C8
168

CYP2C19
293
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2B6
1001
 no
CYP2C19
1553
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2C8
965
 no
CYP2C9
1819
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP2D6
1891
 no
CYP3A4
1925
 no
CYP3A4
1925
 no
OAT1
603
 no
OAT3
644
 no
OATP1B1
803
 no
OATP1B3
715
 no
OCT1
543
 no
OCT2
648
 no
P-gp
1650
 no
BCRP
773
 yes [IC50 51.1 uM]
yes (co-administration study)
Comment: Coadministration of multiple oral doses of SIVEXTRO (200 mg once daily) increased the Cmax and AUC of rosuvastatin (10 mg single oral dose), a known BCRP substrate, by approximately 55% and 70%, respectively, in healthy adult subjects
Page: 10.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1054
 no
CYP2B6
664
 no
CYP2C19
991
 no
CYP2C8
693
 no
CYP2C9
1037
 no
CYP2D6
1217
 no
CYP3A4
1737
 no
OAT1
326
 no
OAT3
339
 no
OATP1B1
406
 no
OATP1B3
350
 no
OCT1
327
 no
OCT2
355
 no
P-gp
1537
 no
SULT1A1
29
 yes
SULT2A1
24
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:82717
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:82717
ChemicalBook
CB02484972
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB02484972
MolPort
MolPort-042-624-220
https://www.molport.com/shop/molecule-link/MolPort-042-624-220
ZINC
ZINC000043100956
http://zinc15.docking.org/substances/ZINC000043100956
PubMed

PubMed

TitleDatePubMed
Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
2014 Aug
Patents

Patents

20070155798
3
20090192197
3
20100093669
3
20100227839
3
20100305069
3
20130102523
3

Sample Use Guides

In Vivo Use Guide
Curator's Comment: SIVEXTRO (tedizolid phosphate) tablet, for oral use or SIVEXTRO (tedizolid phosphate) for injection, for intravenous use.
The recommended dosage of SIVEXTRO is 200 mg administered once daily for six (6) days either orally (with or without food) or as an intravenous (IV) infusion in patients 18 years of age or older.
Route of Administration: Oral
In Vitro Use Guide
At least 90% of the microorganisms (Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillinsusceptible [MSSA] isolates); Streptococcus pyogenes; Streptococcus agalactiae; Streptococcus anginosus Group (including S. anginosus, S. intermedius, and S. constellatus); Enterococcus faecalis; Staphylococcus epidermidis (including methicillin-susceptible and methicillin-resistant isolates); Staphylococcus haemolyticus; Staphylococcus lugdunensis; Enterococcus faecium) exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to 0.5 mcg/mL for tedizolid.
Name Type Language
TOREZOLID PHOSPHATE DISODIUM
Common Name English
TEDIZOLID PHOSPHATE DISODIUM SALT [MI]
Common Name English
2-OXAZOLIDINONE, 3-(3-FLUORO-4-(6-(2-METHYL-2H-TETRAZOL-5-YL)-3-PYRIDINYL)PHENYL)-5-((PHOSPHONOOXY)METHYL)-, SODIUM SALT (1:2), (5R)-
Systematic Name English
TR-701
Code English
DA-7218
Code English
TEDIZOLID PHOSPHATE DISODIUM SALT
MI  
Common Name English
TEDIZOLID PHOSPHATE DISODIUM
Common Name English
Tedizolid phosphate disodium [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
0SVV6ZD7JQ
Created by admin on Fri Dec 15 16:18:31 GMT 2023 , Edited by admin on Fri Dec 15 16:18:31 GMT 2023
PRIMARY
CHEBI
83326
Created by admin on Fri Dec 15 16:18:31 GMT 2023 , Edited by admin on Fri Dec 15 16:18:31 GMT 2023
PRIMARY
MERCK INDEX
m10517
Created by admin on Fri Dec 15 16:18:31 GMT 2023 , Edited by admin on Fri Dec 15 16:18:31 GMT 2023
PRIMARY Merck Index
CAS
856867-39-5
Created by admin on Fri Dec 15 16:18:31 GMT 2023 , Edited by admin on Fri Dec 15 16:18:31 GMT 2023
PRIMARY
PUBCHEM
11477442
Created by admin on Fri Dec 15 16:18:31 GMT 2023 , Edited by admin on Fri Dec 15 16:18:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID70234976
Created by admin on Fri Dec 15 16:18:31 GMT 2023 , Edited by admin on Fri Dec 15 16:18:31 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of TEDIZOLID
PARENT (SALT/SOLVATE)
Structure of TEDIZOLID PHOSPHATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966